Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. scores highest on Earnings (83) and lowest on Anchor (33). Its PosiPenta is 66.10 out of 100, better than most similar companies.
On the Penta Grid this week, Protalix BioTherapeutics, Inc. is Grid #46 of 837 in the Healthcare sector in United States, and Grid #163 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Protalix BioTherapeutics, Inc. | 66.10 | 62 | 83 | 82 | 71 | 33 |
| Alector, Inc. | 34.46 | 0 | 46 | 57 | 12 | 57 |
| Pyxis Oncology, Inc. | 27.64 | 3 | 39 | 35 | 15 | 47 |
| RxSight, Inc. | 45.37 | 43 | 48 | 24 | 64 | 47 |
| Pro-Dex, Inc. | 64.12 | 54 | 54 | 79 | 64 | 70 |
| Glass House Brands Inc. | 41.38 | 16 | 71 | 19 | 47 | 55 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | 11.39 |
| P/B ratio | 2.96 |
EEarnings
| Trailing EPS | ₹21.78 |
| Forward EPS | ₹58.72 |
NNitro
| Price | 248.15 |
| 52-week high | 302.14 |
| 52-week low | 151.54 |
| Fall from 52-week high | 17.9% |
TTorque
| Return on equity (ROE) | 31.23% |
| Debt-to-equity | 0.13 |
AAnchor
| Beta (price swings) | -0.09 |
| Market cap | ₹1,999 Cr |
| Insider holding | 3.88% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Protalix BioTherapeutics, Inc.'s PosiPenta score?
Protalix BioTherapeutics, Inc.'s PosiPenta is 66.10 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Protalix BioTherapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Protalix BioTherapeutics, Inc. is Grid #46 of 837 in the Healthcare sector in United States, and Grid #163 of 4,000 in United States.
Which PosiPenta pillar is strongest for Protalix BioTherapeutics, Inc.?
Earnings (growth), with a score of 83 out of 100: much better than most similar companies.
Which PosiPenta pillar is weakest for Protalix BioTherapeutics, Inc.?
Anchor (stability and dividends), with a score of 33 out of 100: weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.